• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLCO alert in real time by email
    • Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt

    GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.

    "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," said Zsolt Harsanyi, Ph.D., chairman of the Board of Directors. "He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry. Joe has a solid track record of driving growth and successfully navigating companies through periods of transformation. His leadership will be instrumental in strengthening Emergent's balance sheet and returning to growth, as we continue to deliver on our mission to protect and enhance life. On behalf of the Board, I would also like to thank Haywood Miller for his leadership and contributions during this interim period."

    "Whether it's increasing access to NARCAN® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver important medical countermeasures to customers around the world, Emergent is providing critical products to address global health crises," said Mr. Papa. "I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness. I look forward to working with the team to accelerate the company's progress, continue improving its financial position and drive value for shareholders. It is a privilege to join Emergent and chart a new chapter in this vital space."

    "Over the past several months, I am encouraged by our achievements in strengthening Emergent's financial foundation and core products business," stated Mr. Miller. "It has been an honor to lead Emergent during this period of transition, and I am confident the company is well positioned for the future as a leader in global preparedness and public health."

    2023 Key Milestones & Accomplishments

    Emergent's sharpened strategic focus delivered several key accomplishments in 2023, including:

    Strengthened Portfolio

    • Launched NARCAN® Nasal Spray over-the-counter opioid overdose reversal treatment in the U.S., in addition to distributing over 20 million doses (10 million two-dose boxes) in the U.S. and Canada
    • Secured a new $235.8 million contract with U.S. Dept. of Defense for BioThrax® (Anthrax Vaccine Adsorbed)
    • Signed a new $379.6 million U.S. Dept. of Defense contract for RSDL® (Reactive Skin Decontamination Lotion Kit)
    • Received U.S. FDA approval of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), formerly AV7909, a two-dose anthrax vaccine for post-exposure prophylaxis use
    • Awarded a $75 million option to Emergent's existing contract for the acquisition of anthrax vaccine CYFENDUS®
    • Awarded a 10-year contract by BARDA for advanced development, manufacturing scale-up, and procurement of Ebanga™ (ansuvimab-zykl), a treatment for Ebola
    • Submitted a supplemental Biologics License Application to the FDA for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) vaccine for immunization against Mpox virus

    Improved Financial Position

    • Implemented organizational changes resulting in $60 million in annual savings
    • Shifted resource deployment resulting in $100 million in annual savings
    • Amended and extended maturity of our secured credit facility to May 2025
    • Travel Health business divestiture – valued at up to $380 million

    About Joseph C. Papa

    Mr. Papa brings over 35 years of experience in the healthcare and pharmaceutical industry, having most recently served as Chief Executive Officer and Chairman at Bausch and Lomb Corporation ("Bausch and Lomb") (NYSE:BLCO) a global eye health company. During his tenure, Papa successfully led the Company's IPO in May 2022 to raise $630 million. Prior to his role at Bausch and Lomb, Papa was the Chief Executive Officer and Chairman of Bausch Health.

    He previously served as the Chairman and CEO of Perrigo, a private-label over-the-counter pharmaceuticals manufacturer, and led the pharmaceutical and technologies services division at Cardinal Health, a healthcare services and distribution company. Before that, Papa held the role of President and Chief Operating Officer at Watson Pharmaceuticals and worked for 14 years at Novartis Pharmaceuticals in the U.S. and Switzerland.

    About Emergent BioSolutions 

    At Emergent, our mission is to protect and enhance life. For 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X (formerly Twitter), and Instagram.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances. 

    There are a number of important factors that could cause our actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements. 

    Investor Contact:

    Richard S. Lindahl

    Executive Vice President, CFO

    [email protected]

    Media Contact:

    Assal Hellmer

    Vice President, Communications

    [email protected] 



    Primary Logo

    Get the next $BLCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCO
    $EBS

    CompanyDatePrice TargetRatingAnalyst
    Bausch + Lomb Corporation
    $BLCO
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    Bausch + Lomb Corporation
    $BLCO
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    Emergent BioSolutions Inc.
    $EBS
    12/30/2024$15.00Buy
    H.C. Wainwright
    Bausch + Lomb Corporation
    $BLCO
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    Bausch + Lomb Corporation
    $BLCO
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    Bausch + Lomb Corporation
    $BLCO
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    Emergent BioSolutions Inc.
    $EBS
    8/22/2024$16.00Buy
    Rodman & Renshaw
    Bausch + Lomb Corporation
    $BLCO
    7/10/2024$19.00Outperform
    Raymond James
    More analyst ratings

    $BLCO
    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

      H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      5/2/25 7:51:06 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

      3/28/25 8:14:16 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

      H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

      12/30/24 7:24:57 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCO
    $EBS
    Leadership Updates

    Live Leadership Updates

    See more
    • Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

      Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

      11/4/24 7:30:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

      Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg

      10/8/24 5:32:28 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLCO
    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Emergent BioSolutions Reports First Quarter 2025 Financial Results

      First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

      5/7/25 4:05:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today's announcement reinforces Bausch + Lomb's commitment to equip cataract surgeons with choices to fit the right lens to the right patient following the recent launches of enVista® Envy™ full range of vision lenses in the United States and Canada and enVista Aspire™ intermediate-optimized IOLs in Europe. "This platform has delivered both quality of vision and patient satis

      5/7/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

      WINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the Ontario Ministry of Health with NARCAN® Nasal Spray for the Ontario Naloxone Program (ONP). Since 2018, Emergent has supported the Ontario Ministry of Health to provide access to NARCAN® Nasal Spray across the province. NARCAN® Nasal Spray is designed to reverse the effects of an opioid poisoning in minutes and is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years (48 months). From January through March 2025, there were 653 suspect drug-related fatalities in Ontario

      5/1/25 5:07:20 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCO
    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Emergent BioSolutions Inc.

      SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

      11/13/24 4:00:18 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

      SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

      11/8/24 5:23:28 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

      SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

      9/10/24 12:09:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCO
    $EBS
    Financials

    Live finance-specific insights

    See more
    • Emergent BioSolutions Reports First Quarter 2025 Financial Results

      First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

      5/7/25 4:05:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch + Lomb Announces First-Quarter 2025 Results

      Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

      4/30/25 6:57:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

      GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be a

      4/22/25 8:00:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCO
    $EBS
    SEC Filings

    See more
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/7/25 4:08:56 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/6/25 4:19:14 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bausch + Lomb Corporation

      10-Q - Bausch & Lomb Corp (0001860742) (Filer)

      4/30/25 4:17:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Robertson Russel C was granted 2,210 shares, increasing direct ownership by 5% to 44,576 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/5/25 4:02:01 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Paulson John was granted 1,887 shares, increasing direct ownership by 4% to 49,627 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/5/25 4:00:47 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care